We were delighted to talk to Dr Enrique Grande (MD Anderson Cancer Center, Madrid) about clinical trial development of neuroendocrine tumours. The abstract ‘Clinical Trials in Europe’ was presented at the virtual 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference 2021.
Questions:
- Could you give us a brief overview of the different approaches to the treatment of neuroendocrine tumours (NETs) that are currently in advanced clinical trial development in Europe? (0:12-0:55)
- What has been the most exciting clinical trial data to emerge in the last year? (0:56- 2:05)
- What are the key take-home messages of your presentation? (2:06-3:21)
Disclosures: Honoraria for speaker engagements, advisory roles or funding of continuous medical education: Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma, Thermo Fisher Scientific. Research Grants: Astellas, Astra Zeneca, IPSEN, Lexicon, MTEM/Threshold, Nanostring Technologies, Pfizer, Roche. Leadership roles in medical societies: ENETS, GETNE and GETHI. Private Healthcare provider: MD Anderson Cancer Center Madrid (workplace). Commercial Medical Education provider: Universidad Europea de Madrid (UEM), Universidad CEU Cardenal Herrera, Universidad Rey Juan Carlos, Oncinfo
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENETS 2021 (Virtual).
